AKT1 and cancer: Consequently, targeting the Akt-mTOR pathway has emerged as a potential therapeutic strategy against this challenging cancer, with ongoing research focused on developing inhibitors/antibodies and combination therapies to improve treatment outcomes for OS [10, 42–44, 48, 49].